Security
Cyclerion Therapeutics, Inc. Common Stock · CYCN
CYCNNASDAQCommon stockCurrentCIK 1755237Updated Oct 4, 2026
Name history
Cyclerion Therapeutics, Inc. · through Aug 27, 2026
CYCN price & chart
Loading TradingView…
NASDAQ:CYCN on TradingView ↗About the company
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com and follow the Company on LinkedIn.
In the news
Recent filings
SCHEDULE 13D - filed by Fairmount Funds Management LLC regarding Korsana Biosciences, Inc.
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics · Change in Shell Company Status · Regulation FD Disclosure
Items 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01, 9.01
4 filing
3 filing
3 filing
Show 5 more recent filings
3 filing
Submission of Matters to a Vote of Security Holders · Other Events
Items 5.07, 8.01, 9.01
425 filing
Other Events
Items 8.01
425 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,985,000Source | 9,575,000Source | 13,374,000Source | 18,079,000Source |
| Property, Plant and Equipment, NetUSD | — | 0Source | 0Source | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,240,000Source | 3,232,000Source | 7,571,000Source | 13,382,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,000,000Source | 556,000Source | 0Source | 96,000Source |
| Assets, CurrentUSD | 4,635,000Source | 4,225,000Source | 8,024,000Source | 14,820,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 0Source | 1,218,000Source |
| Other Assets, NoncurrentUSD | — | — | 0Source | 2,041,000Source |
| LIABILITIES AND EQUITY | ||||
| Commitments and ContingenciesUSD | 0Source | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -271,020,000Source | -267,492,000Source | -264,417,000Source | -259,154,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 0Source | -12,000Source | -20,000Source |
| Stockholders' Equity Attributable to ParentUSD | 9,085,000Source | 8,850,000Source | 11,288,000Source | 10,452,000Source |
| Additional Paid in Capital, Common StockUSD | 280,105,000Source | 276,342,000Source | 275,717,000Source | 269,626,000Source |
| Liabilities and EquityUSD | 9,985,000Source | 9,575,000Source | 13,374,000Source | 18,079,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 900,000Source | 725,000Source | 2,086,000Source | 7,627,000Source |
| Accounts Payable, CurrentUSD | 508,000Source | 390,000Source | 1,198,000Source | 2,970,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -3,528,000Source | -3,057,000Source | -5,263,000Source | -44,078,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 441,000Source | 625,000Source | 1,067,000Source | 6,252,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 444,000Source | 556,000Source | -96,000Source | -4,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -3,314,000Source | -4,333,000Source | -21,245,000Source | -40,611,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 0Source | 10,402,000Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 0Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 3,322,000Source | 0Source | 5,024,000Source | 29,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,000Source | -4,339,000Source | -5,811,000Source | -40,579,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,240,000Source | 3,232,000Source | 7,571,000Source | 13,382,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 0Source | -6,000Source | 8,000Source | 3,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 441,000Source | 625,000Source | 1,067,000Source | 6,252,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 6,088,000Source | 5,342,000Source | 8,132,000Source | 14,504,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | -3,057,000Source | -12,593,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 0Source | 7,330,000Source | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -3,528,000Source | -3,057,000Source | -5,263,000Source | -44,078,000Source |
| Nonoperating Income (Expense)USD | 1,445,000Source | 571,000Source | 358,000Source | 294,000Source |
| Operating ExpensesUSD | 7,047,000Source | 5,628,000Source | 12,951,000Source | 45,997,000Source |
| Operating Lease, Impairment LossUSD | — | — | 3,300,000Source | — |
| Proceeds from Issuance of Common StockUSD | 1,375,000Source | 0Source | 5,000,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,074,000Source | 2,000,000Source | 0Source | 1,625,000Source |
| Operating Income (Loss)USD | -4,973,000Source | -3,628,000Source | -12,951,000Source | -44,372,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -3,528,000Source | -3,057,000Source | -5,263,000Source | -44,078,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -3,528,000Source | -3,057,000Source | -5,263,000Source | -44,078,000Source |
| Earnings Per Share, BasicUSD per share | -1.11Source | -1.21Source | -2.25Source | -1.01Source |
| Earnings Per Share, DilutedUSD per share | -1.11Source | -1.21Source | -2.25Source | -1.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 3,181,000Source | 2,518,000Source | 2,338,000Source | 43,469,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 3,181,000Source | 2,518,000Source | 2,338,000Source | 43,469,000Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 0Source | 65,000Source |
| General and Administrative ExpenseUSD | 6,088,000Source | 5,342,000Source | 8,132,000Source | 14,504,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -3,528,000Source | -3,060,000Source | -5,181,000Source | -44,063,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | -3,057,000Source | -12,593,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -1.21Source | -5.39Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -1.21Source | -5.39Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 0Source | 7,330,000Source | — |
| Nonoperating Income (Expense)USD | 1,445,000Source | 571,000Source | 358,000Source | 294,000Source |
| Operating ExpensesUSD | 7,047,000Source | 5,628,000Source | 12,951,000Source | 45,997,000Source |
| Research and Development ExpenseUSD | 959,000Source | 286,000Source | 1,515,000Source | 31,493,000Source |
Offerings
Registration 333-295175
Filing attachments
d178159dex42.htm · 8-K · 2026-09-11
EX-4.2 6 d178159dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗d178159dex991.htm · 8-K · 2026-09-11
EX-99.1 16 d178159dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer’s patients anticipated by year-end 2027 or first quarter of 2028 Strong financial position with post-transaction cash and cash equivalents of appro…
Read attachment ↗d178159dex992.htm · 8-K · 2026-09-11
EX-99.2 17 d178159dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 KORSANA BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) June 30, December 31, …
Read attachment ↗d111069dex42.htm · S-4 · 2026-04-20
EX-4.2 4 d111069dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 Confidential Final Form THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUAN…
Read attachment ↗d111069dex991.htm · S-4 · 2026-04-20
EX-99.1 17 d111069dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Consent to be Named as a Director Cyclerion Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements theret…
Read attachment ↗d111069dex992.htm · S-4 · 2026-04-20
EX-99.2 18 d111069dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Consent to be Named as a Director Cyclerion Therapeutics, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements theret…
Read attachment ↗